FDA.reportPublic FDA data

fingolimod 0.25 MG Disintegrating Oral Tablet

RxCUI
2610295
RxNorm name
fingolimod 0.25 MG Disintegrating Oral Tablet
Display name
fingolimod 0.25 MG Disintegrating Oral Tablet
Full name
fingolimod 0.25 MG Disintegrating Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:19

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TASCENSO ODTFINGOLIMOD LAURYL SULFATECycle Pharmaceuticals Ltdbf8e7f89-ea09-43c7-a7eb-e447243507212026-01-20Warnings, Adverse reactionsExact identifier
rxcui: 2610295

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
bf8e7f89-ea09-43c7-a7eb-e44724350721fingolimod 0.25 MG Disintegrating Oral Tablet [PSN] · fingolimod 0.25 MG Disintegrating Oral Tablet [SCD] · fingolimod 0.25 MG (as fingolimod lauryl sulfate 0.47 MG) Disintegrating Oral Tablet [SY]38These highlights do not include all the information needed to use TASCENSO ODT ® safely and effectively. See full prescribing information for TASCENSO ODT. TASCENSO ODT (fingolimod) orally disintegrating tablets Initial U.S. Approval: 201020260108